GLP-1 and Weight Loss Studies: A Comprehensive Review
Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a promising class of medications for weight loss, particularly among individuals with obesity. These medications work by mimicking the action of the naturally occurring hormone GLP-1, which plays a key role in regulating appetite, glucose metabolism, and weight management.
Background and Rationale
GLP-1 receptor agonists have been extensively studied for their efficacy and safety in managing type 2 diabetes. However, their use has also been expanding to include weight loss and other cardiometabolic applications. Recent studies have shed light on their potential benefits and risks, including their effects on weight loss, cardiovascular health, and mental well-being.
GLP-1 Mechanism of Action and Weight Loss Efficacy
GLP-1 receptor agonists work by increasing insulin secretion, decreasing glucagon levels, and delaying gastric emptying. This leads to increased satiety, reduced food intake, and improved glucose control. The efficacy of GLP-1 receptor agonists in promoting weight loss has been demonstrated in numerous randomized controlled trials, with some studies showing significant reductions in body weight, body mass index (BMI), and waist circumference.
Long-Term Efficacy and Safety of GLP-1 Receptor Agonists
Recent studies have investigated the long-term efficacy and safety of GLP-1 receptor agonists in managing obesity. A systematic review published in 2025 evaluated the data from high-quality randomized controlled trials and found that GLP-1 receptor agonists were associated with significant weight loss and improved glycemic control. However, the review also highlighted the potential risks of discontinuation, including weight regain and gastrointestinal adverse events.
